Share：
Share this content in WeChat
X
[Chinese][PDF]80374
• Review •
The inflammatory mechanism of pancreatic cancer and its theranostic significance
GUO Hang  WANG Chunlei  YU Dexin 

Cite this article as: Guo H, Wang CL, Yu DX. The inflammatory mechanism of pancreatic cancer and its theranostic significance. Chin J Magn Reson Imaging, 2019, 10(11): 873-876. DOI:10.12015/issn.1674-8034.2019.11.018.


[Abstract] It is well known that pancreatic ductal adeno-carcinoma (PDAC) is a highly aggressive malignancy with very poor prognosis, and most were first diagnosed with local advancement or metastasis. Considering its poor response to traditional chemotherapy and radiotherapy, it is crucial that the patients can be diagnosed and treated at an early stage. Inflammation has a tight relationship with tumorigenesis and tumor progression, and chronic aseptic inflammation of pancreas is one of the most important risk factors of pancreatic cancer. As nanotechnology shows great promise against malignant diseases like pancreatic cancer, more and more researches were conducted to exploit the characteristics of nanocarriers for their application in both diagnosis and treatment of malignancies. In this review, we summarize the role of inflammation in PDAC and its significance to both diagnostic and therapeutic strategies.
[Keywords] pancreatic neoplasms；inflammation；theranostics

GUO Hang Department of Radiology, Qilu Hospital of Shandong University, Jinan 250000, China

WANG Chunlei Emergency Department, Weifang People's Hospital of Shandong Province, Weifang 261000, China

YU Dexin * Department of Radiology, Qilu Hospital of Shandong University, Jinan 250000, China

*Corresponding to: Yu DX, E-mail: ydx0330@sina.com

Conflicts of interest   None.

ACKNOWLEDGMENTS  This article is supported by the National Natural Science Found No. 81771888
Received  2019-07-22
DOI: 10.12015/issn.1674-8034.2019.11.018
Cite this article as: Guo H, Wang CL, Yu DX. The inflammatory mechanism of pancreatic cancer and its theranostic significance. Chin J Magn Reson Imaging, 2019, 10(11): 873-876. DOI:10.12015/issn.1674-8034.2019.11.018.

[1]
Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357(9255): 539-545.
[2]
Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res, 2006, 4(4): 221-233.
[3]
Karin M. NF-kappaB and cancer: mechanisms and targets. Mol Carcinog, 2006, 45(6): 355-61.
[4]
Zhuang Z, Ju HQ, Aguilar M, et al. IL1 receptor antagonist inhibits pancreatic cancer growth by abrogating NF-kappaB activation. Clin Cancer Res, 2016, 22(6): 1432-1444.
[5]
D'Amico S, Shi J, Martin BL, et al. STAT3 is a master regulator of epithelial identity and KRAS-driven tumorigenesis. Genes Dev, 2018, 32(17-18): 1175-1187.
[6]
Venkatasubbarao K. Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. Mol Cancer, 2013, 12(1): 104.
[7]
Ahmed S, Bradshaw AD, Gera S, et al. The TGF-beta/Smad4 signaling pathway in pancreatic carcinogenesis and its clinical significance. J Clin Med, 2017, 6(1): 5.
[8]
Hagopian MM, Brekken RA. Stromal TGFbetaR2 signaling: a gateway to progression for pancreatic cancer. Mol Cell Oncol, 2015, 2(3): e975606.
[9]
Balkwill F. Tumour necrosis factor and cancer. Nature Reviews Cancer, 2009, 9: 361.
[10]
Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol, 2014, 6(10): a016295.
[11]
Kumari N, Dwarakanath BS, Das A, et al. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol, 2016, 37(9): 11553-11572.
[12]
Apte RN, Voronov E. Is interleukin-1 a good or bad 'guy’ in tumor immunobiology and immunotherapy? Immunological Reviews, 2008, 222(1): 222-241.
[13]
Elkabets M, Krelin Y, Dotan S, et al. Host-derived interleukin-1alpha is important in determining the immunogenicity of 3-methylcholantrene tumor cells. J Immunol, 2009, 182(8): 4874-4881.
[14]
Ghassem-Zadeh S, Gaida MM, Szanyi S, et al. Distinct pathophysiological cytokine profiles for discrimination between autoimmune pancreatitis, chronic pancreatitis, and pancreatic ductal adenocarcinoma. J Transl Med, 2017, 15(1): 126.
[15]
Holmer R, Goumas FA, Waetzig GH, et al. Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreatic Dis Intl, 2014, 13(4): 371-380.
[16]
Zhang D, Li L, Jiang H, et al. Tumor-stroma IL1beta-IRAK4 feedforward circuitry drives tumor fibrosis, chemoresistance, and poor prognosis in pancreatic cancer. Cancer Res, 2018, 78(7): 1700-1712.
[17]
Dannenberg AJ, Lippman SM, Mann JR, et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol, 2005, 23(2): 254-266.
[18]
Hu H, Han T, Zhuo M, et al. Elevated COX-2 expression promotes angiogenesis through EGFR/p38-MAPK/Sp1-dependent signalling in pancreatic cancer. Sci Rep, 2017, 7(1): 470.
[19]
Wang J, Hussain SP. NO(*) and pancreatic cancer: a complex interaction with therapeutic potential. Antioxid Redox Signal, 2017, 26(17): 1000-1008.
[20]
Camp ER, Yang A, Liu W, et al. Roles of nitric oxide synthase inhibition and vascular endothelial growth factor receptor-2 inhibition on vascular morphology and function in an in vivo model of pancreatic cancer. Clin Cancer Res, 2006, 12(8): 2628-2633.
[21]
Guillen-Ponce C, Blazquez J, Gonzalez I, et al. Diagnosis and staging of pancreatic ductal adenocarcinoma. Clin Transl Oncol, 2017, 19(10): 1205-1216.
[22]
Horvat N, Ryan DE, LaGratta MD, et al. Imaging for pancreatic ductal adenocarcinoma. Chin Clin Oncol, 2017, 6(6): 62.
[23]
Zhou Z, Lu ZR. Molecular imaging of the tumor microenvironment. Adv Drug Deliv Rev, 2017, 113: 24-48.
[24]
Neuzillet C, Tijeras-Raballand A, Bourget P, et al. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther, 2015, 155: 80-104.
[25]
Incio J, Liu H, Suboj P, et al. Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. Cancer Discov, 2016, 6(8): 852-869.
[26]
Egberts JH, Cloosters V, Noack A, et al. Anti-tumor necrosis factor therapy inhibits pancreatic tumor growth and metastasis. Cancer Res, 2008, 68(5): 1443-1450.
[27]
Capurso G, Schunemann HJ, Terrenato I, et al. Meta-analysis: the use of non-steroidal anti-inflammatory drugs and pancreatic cancer risk for different exposure categories. Aliment Pharmacol Ther, 2007, 26(8): 1089-1099.
[28]
Feig C, Gopinathan A, Neesse A, et al. The pancreas cancer microenvironment. Clin Cancer Res, 2012, 18(16): 4266-4276.
[29]
Wagner V, Dullaart A, Bock AK, et al. The emerging nanomedicine landscape. Nature Biotechnol, 2006, 24: 1211.
[30]
Shi J, Votruba AR, Farokhzad OC, et al. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett, 2010, 10(9): 3223-3230.
[31]
Borsoi C, Leonard F, Lee Y, et al. Gemcitabine enhances the transport of nanovector-albumin-bound paclitaxel in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Lett, 2017, 403: 296-304.
[32]
Liu X, Lin P, Perrett I, et al. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer. J Clin Invest, 2017, 127(5): 2007-2018.
[33]
Clawson GA, Abraham T, Pan W, et al. A Cholecystokinin B receptor-specific DNA aptamer for targeting pancreatic ductal adenocarcinoma. Nucleic Acid Ther, 2017, 27(1): 23-35.
[34]
Cabral H, Matsumoto Y, Mizuno K, et al. Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. Nat Nanotechnol, 2011, 6(12): 815-823.
[35]
Hirsch LR, Stafford RJ, Bankson JA, et al. Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A, 2003, 100(23): 13549-13554.
[36]
Thorek DL, Chen AK, Czupryna J, et al. Superparamagnetic iron oxide nanoparticle probes for molecular imaging. Ann Biomed Eng, 2006, 34(1): 23-38.
[37]
Huang J, Li Y, Orza A, et al. Magnetic nanoparticle facilitated drug delivery for cancer therapy with targeted and image-guided approaches. Adv Funct Mater, 2016, 26(22): 3818-3836.

PREV The application progress of magnetic resonance future tracking technique to evaluate myocardial strain
NEXT Advances in neuroimaging of inflammatory bowel disease
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn